These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33671256)

  • 1. Identification and Characterization of Mortaparib
    Sari AN; Elwakeel A; Dhanjal JK; Kumar V; Sundar D; Kaul SC; Wadhwa R
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1.
    Meidinna HN; Shefrin S; Sari AN; Zhang H; Dhanjal JK; Kaul SC; Sundar D; Wadhwa R
    Front Cell Dev Biol; 2022; 10():918970. PubMed ID: 36172283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53
    Elwakeel A; Sari AN; Dhanjal JK; Meidinna HN; Sundar D; Kaul SC; Wadhwa R
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
    Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
    J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixtures of Three Mortaparibs with Enhanced Anticancer, Anti-Migration, and Antistress Activities: Molecular Characterization in p53-Null Cancer Cells.
    Wadhwa R; Yang S; Meidinna HN; Sari AN; Bhargava P; Kaul SC
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
    Grover A; Priyandoko D; Gao R; Shandilya A; Widodo N; Bisaria VS; Kaul SC; Wadhwa R; Sundar D
    Int J Biochem Cell Biol; 2012 Mar; 44(3):496-504. PubMed ID: 22155302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational and in vitro experimental analyses of the Anti-COVID-19 potential of Mortaparib and MortaparibPlus.
    Kumar V; Sari AN; Meidinna HN; Dhanjal JK; Subramani C; Basu B; Kaul SC; Vrati S; Sundar D; Wadhwa R
    Biosci Rep; 2021 Oct; ():. PubMed ID: 34605873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far.
    Elwakeel A
    Front Cell Dev Biol; 2022; 10():879632. PubMed ID: 35493098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines.
    Gestl EE; Anne Böttger S
    Biochem Biophys Res Commun; 2012 Jun; 423(2):411-6. PubMed ID: 22683628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening.
    Utomo DH; Widodo N; Rifa'i M
    Bioinformation; 2012; 8(9):426-9. PubMed ID: 22715313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin.
    Lu WJ; Lee NP; Kaul SC; Lan F; Poon RT; Wadhwa R; Luk JM
    Int J Cancer; 2011 Oct; 129(8):1806-14. PubMed ID: 21165951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.
    Shankaranarayana AH; Meduri B; Pujar GV; Hariharapura RC; Sethu AK; Singh M; Bidye D
    Future Med Chem; 2023 Nov; 15(22):2087-2112. PubMed ID: 37877348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why is Mortalin a Potential Therapeutic Target for Cancer?
    Yoon AR; Wadhwa R; Kaul SC; Yun CO
    Front Cell Dev Biol; 2022; 10():914540. PubMed ID: 35859897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fucoxanthin induces growth arrest and apoptosis in human bladder cancer T24 cells by up-regulation of p21 and down-regulation of mortalin.
    Wang L; Zeng Y; Liu Y; Hu X; Li S; Wang Y; Li L; Lei Z; Zhang Z
    Acta Biochim Biophys Sin (Shanghai); 2014 Oct; 46(10):877-84. PubMed ID: 25187415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.
    Nigam N; Grover A; Goyal S; Katiyar SP; Bhargava P; Wang PC; Sundar D; Kaul SC; Wadhwa R
    PLoS One; 2015; 10(9):e0138192. PubMed ID: 26376435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells.
    Wadhwa R; Takano S; Taira K; Kaul SC
    J Gene Med; 2004 Apr; 6(4):439-44. PubMed ID: 15079818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico analysis of the binding properties of solasonine to mortalin and p53, and in vitro pharmacological studies of its apoptotic and cytotoxic effects on human HepG2 and Hep3b hepatocellular carcinoma cells.
    Pham MQ; Tran THV; Pham QL; Gairin JE
    Fundam Clin Pharmacol; 2019 Aug; 33(4):385-396. PubMed ID: 30628118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics-based identification of novel natural mortalin-p53 abrogators as anticancer agents.
    Nagpal N; Goyal S; Dhanjal JK; Ye L; Kaul SC; Wadhwa R; Chaturvedi R; Grover A
    J Recept Signal Transduct Res; 2017 Feb; 37(1):8-16. PubMed ID: 27380217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Lloyd RV; Park JI
    Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
    Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.